Psoriasis
From the Journals
Study results suggest ustekinumab may trigger acute CV events early in treatment
French researchers urge caution in prescribing drug for high-risk patients.
From the Journals
Biologics for psoriasis may also reduce coronary plaque
Cardiac CT scans reveal a reduction in lipid-rich necrotic core (LRNC) in patients who were receiving biologics.
From the Journals
COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
No increase was seen in hospitalization and death rates, providing additional support for keeping patients on these immunosuppressive treatments...
Original Research
Content Analysis of Psoriasis and Eczema Direct-to-Consumer Advertisements
Direct-to-consumer (DTC) advertisements have been associated with both beneficial and detrimental effects on real-world health care utilization....
Feature
Psoriasis, PsA, and pregnancy: Tailoring treatment with increasing data
Two experts give their up-to-date views on managing psoriasis and psoriatic arthritis before, during, and after pregnancy.
Feature
The long road to a PsA prevention trial
Researchers zero in on biologics, diet, and risk modeling to craft studies on a challenging population.
From the Journals
TNF inhibitors linked to inflammatory CNS events
The authors do not caution “against using these therapies in appropriate patients,” and it is unclear whether this association “represents de novo...
Latest News
Humira topped drug-revenue list for 2019
Three cytokine inhibitors were among the four best-selling drugs last year.
Clinical Review
Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Phototherapy
In July 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released an updated set of guidelines...
Case Letter
Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis
Palmoplantar psoriasis is challenging to treat and is unresponsive to many modalities. Combination, rotational, and sequential treatment...
Conference Coverage
Beyond PASI 100: striving for molecular clearance
A PASI 100 response, traditionally considered unreachable for most patients with severe psoriasis, soon just might not be good enough.